We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ablynx Enters into a Research and License Agreement with Wyeth

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ablynx Enters into a Research and License Agreement with Wyeth"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Ablynx has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, to discover, develop and commercialise Nanobodies® directed at the tumour necrosis factor alpha (TNF-a) protein and its receptors that target diseases in multiple therapeutic areas.

Ablynx has granted Wyeth exclusive worldwide rights to Nanobodies® targeting the clinically validated target TNF- a. 

Ablynx and Wyeth will collaborate to advance these novel biologics through preclinical development. 

Ablynx will receive an initial payment, research support and milestone payments. 

Potential payments to Ablynx could total up to $212.5 million for the development and commercialisation of multiple products. In addition Ablynx will receive royalties on product sales. 

The alliance is based on Ablynx’s Nanobody® platform that can be used to create biopharmaceuticals with distinct advantages over current biologics.

Edwin Moses, Chief Executive Officer of Ablynx commented, "We are delighted to have established this strategic collaboration."

"Wyeth has a proven track record in the discovery, development, manufacturing and commercialisation of novel biopharmaceuticals with demonstrated success with Enbrel."

"Wyeth is enthusiastic about this new partnership with Ablynx," said Dr. Frank Walsh, Executive Vice President, Head of Discovery Research, Wyeth Pharmaceuticals.

"Ablynx is an exciting European biotechnology company that has established the feasibility of their novel Nanobody® platform by generating Nanobodies® to more than twenty different targets."

"We look forward to a productive and long lasting partnership with Ablynx."